Repurposing salmon calcitonin for glioblastoma treatment: Targeting Yes-associated Protein (YAP)/ Transcriptional co‑activator with PDZ‑binding motif (TAZ) via hippo pathway activation
Neuro-Oncology Advances · 12.01.2026 · 8 (1)
DOI: 10.1093/noajnl/vdag152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 05.06.2026. Verfasst von Jayita Goswami und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSIR for the graduate fellowship, DST FIST, DBT-IISc.
Abstract (Originalsprache)
Background
Glioblastoma (GBM) remains a deadly brain tumor. Activation of the wild-type calcitonin receptor (CTR) by salmon calcitonin (sCT) suppresses glioma growth, whereas patient-derived CTR mutants drive tumor progression and correlate with poor survival. This study delineates the mechanisms underlying sCT-mediated tumor suppression and reveals structural defects in oncogenic CTR variants.
Methods
Proteome analysis of sCT-treated glioma cells was done to dissect the altered signaling. Multiple experimental approaches were used to elucidate the signaling behind CTR-dependent Hippo pathway activation. The therapeutic efficacy of sCT on the growth of human/murine glioma stem-like cells (GSC)-initiated tumors in an orthotopic mouse glioma model was assessed. Extensive microsecond-scale all-atom molecular dynamics simulations were performed to elucidate the structural impairments in CTR mutants. Results sCT treatment activated Hippo signaling as demonstrated by enhanced phosphorylation and subsequent degradation of YAP/TAZ and suppressed glioma growth through cAMP/PKA/LATS1 signaling in vitro. However, GSCs expressing a phosphorylation-resistant YAP mutant were refractory to sCT treatment in vitro. Both human and murine GSCs exhibited elevated CTR expression, and intranasal administration of sCT effectively inhibited the growth of GSC-initiated tumors. Furthermore, molecular dynamics simulations revealed structural perturbations in CTR interactions with either CT or the Gα subunit.
Conclusions
We establish that activation of the sCT-CTR axis suppresses glioma growth by inhibiting YAP/TAZ through Hippo pathway activation. We further delineate the structural aberrations responsible for the functional loss in patient-derived CTR mutants. Thus, we present compelling evidence supporting the therapeutic repurposing of calcitonin for GBM treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.
- Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India.
ORCID-Profile: Anand Srivastava, Kumaravel Somasundaram
Förderung
- CSIR for the graduate fellowship
- DST FIST
- DBT-IISc
- National Supercomputing Mission grants
- Department of Science and Technology
- DBT-Wellcome Trust India Alliance
- DBT National Network Project
- Science and Engineering Board
Zitieren
APA
Goswami, J., Uttarasili, P., Garg, L., Kaval Reddy, P., Chowdhury, A., Saha, S., Chatterjee, J., Srivastava, A., & Somasundaram, K. (2026). Repurposing salmon calcitonin for glioblastoma treatment: Targeting Yes-associated Protein (YAP)/ Transcriptional co‑activator with PDZ‑binding motif (TAZ) via hippo pathway activation. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag152
Vancouver
Goswami J, Uttarasili P, Garg L, Kaval Reddy P, Chowdhury A, Saha S, et al. Repurposing salmon calcitonin for glioblastoma treatment: Targeting Yes-associated Protein (YAP)/ Transcriptional co‑activator with PDZ‑binding motif (TAZ) via hippo pathway activation. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag152
BibTeX
@article{Goswami2026,
author = {Goswami, Jayita and Uttarasili, Prithviraj and Garg, Lakshay and Kaval Reddy, Prasasvi and Chowdhury, Abhishek and Saha, Subhrodeep and Chatterjee, Jayanta and Srivastava, Anand and Somasundaram, Kumaravel},
title = {Repurposing salmon calcitonin for glioblastoma treatment: Targeting Yes-associated Protein (YAP)/ Transcriptional co‑activator with PDZ‑binding motif (TAZ) via hippo pathway activation},
journal = {Neuro-Oncology Advances},
year = {2026},
volume = {8},
number = {1},
doi = {10.1093/noajnl/vdag152}
}
EUVIMED